Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791318 | 1.00 | NEU3 (0.56) | NEU3NPC1FABP4KMT2AKDM4E | |
| SCHEMBL5329433 | 0.86 | NEU3 (0.60) | NEU3NPC1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL567311 | 0.86 | NEU3 (0.63) | NEU3NPC1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29791247 | 0.86 | NEU3 (0.63) | NEU3NPC1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL4175701 | 0.83 | KDM4E (0.72) | NPC1KMT2AKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL6307782 | 0.83 | KDM4E (0.62) | NEU3KMT2AKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL15894590 | 0.83 | ADRB3 (0.58) | NEU3KMT2AKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL3526841 | 0.81 | ALDH1A1 (0.60) | NEU3NPC1FABP4KMT2AKDM4E | |
| SCHEMBL11225114 | 0.81 | NEU3 (0.58) | NEU3NPC1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL17331322 | 0.81 | CYP2C9 (0.60) | FABP4KMT2AKDM4EHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020017934-A1 | COLORED CURABLE RESIN COMPOSITION, COLOR FILTER, AND DISPLAY APPARATUS | 동우 화인켐 주식회사 | 2020-01-23 | — | — | WO | disclosed |
| US-9308200-B2 | Dry powder formulation comprising a phosphodiesterase inhibitor | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-12 | — | — | US | disclosed |
| US-20150342936-A1 | DRY POWDER FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-03 | — | — | US | disclosed |
| US-9132121-B2 | Dry powder formulation comprising a phosphodiesterase inhibitor | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-15 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1742105-A2 | Photothermographic material | Fuji Photo Film Co., Ltd. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | NEU3 967/4885NPC1 233/4885FABP4 1/4885 |
| US-20150342936-A1 | DRY POWDER FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR | PDE3A, PDE5A, PDE2A | NEU3 1737/4885NPC1 3602/4885FABP4 4054/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | NEU3 1690/4885NPC1 1433/4885FABP4 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.